Macugen PharmaSwiss Ceska Republika s.r.o · Withdrawn · authorised 31 Jan 2006 · ATC S01LA03
Therapeutic indication (EMA)
Macugen is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD).
Active substance
Pegaptanib
- US FDA 1
- EMA 1
- Safety 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| MACUGEN | EQ 0.3MG ACID/0.09ML | injectable · intravitreal | BAUSCH AND LOMB INC | Discontinued | 17 Sep 2004 |
EMA European Union — centrally authorised medicines
Safety signals and safety-related labeling changes
- EMA PRAC 29 Nov 2018 PRAC signal: Artery dissections and aneurysms
Action for MAH: update of the product information: No
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.